Abstract

One of the resistance mechanisms of Pseudomonas aeruginosa, which is an increasing resistance problem to antibiotics, is beta lactamase production. Especially it becomes more and more difficult to apply a treatment to the infections developed by extended spectrum beta lactamase (ESBL) producing strains. It is of importance for the success of the treatment that ESBL is determined in P. aeruginosa and reported to the clinician. In recent years, some ESBL types such as PER-1 in class A and OXA group in class have been determined in P. aeruginosa. These enzymes hydrolyze third generation cefhalosporins and some of them hydrolyze especially cefhtazidimes. In the study, ESBL existence was researched in ceftazidime-resistant (n:50) and cefhtazidim-sensitive (n:20) 70 P. aeruginosa strains with double disc synergy test. ESBL existence was determined in 35 (50%) of the strains. ESBL positivity was reported in cefhtazidime-resistant strains, but not in cephtazidime-sensitive ones. ESBL should be remembered in P. aeruginosa infections not treated with other beta lactam antibiotics except for carbapenem and waste of costs and treatments should be avoided by researching ESBL existence with the help of routine antibiogram tests and double disc synergy method.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call